Morgan Stanley Downgrades Novo Nordisk to Underweight, Maintains Price Target to $40

Benzinga Newsdesk www.benzinga.com Negative 79.2%

Neg 79.2% Neu 0% Pos 0%

Morgan Stanley analyst Thibault Boutherin downgrades Novo Nordisk (NYSE:NVO) from Equal-Weight to Underweight and maintains the price target from $40 to $40.